Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-16

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS

NCT07095686

Amyotrophic Lateral Sclerosis

ENROLLING_BY_INVITATION PHASE1/PHASE2

Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS

NCT06977451

Amyotrophic Lateral Sclerosis

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALS

NCT07095712

Amyotrophic Lateral Sclerosis

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)

NCT01091142

Amyotrophic Lateral Sclerosis

COMPLETED PHASE1

Clinical Trial of High Dose CoQ10 in ALS

NCT00243932

Amyotrophic Lateral Sclerosis Lou Gehrig's Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an interventional study to evaluate the safety and efficacy of treatment with an individualized antisense oligonucleotide (ASO) treatment in a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amyotrophic Lateral Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Open Label

Group Type EXPERIMENTAL

nL-CHCHD-001

Intervention Type DRUG

Personalized antisense oligonucleotide

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nL-CHCHD-001

Personalized antisense oligonucleotide

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent/assent provided by the participant (when appropriate), and/or participant's parent(s) or legally authorized representative(s).
* Ability to travel to the study site and adhere to study-related follow-up examinations and/or procedures and provide access to participant's medical records.
* Genetically confirmed neurological disorder.

Exclusion Criteria

* Participant has any condition that in the opinion of the Site Investigator, would ultimately prevent the completion of study procedures.
* Use of an investigational medication within less than 5 half-lives of the drug at enrollment

Minimum Eligible Age

48 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No